Association between Socioeconomic Status (SES) and Mortality Risk of Gastroenteropancreatic–Neuroendocrine Tumors (GEP–NETs): A Large-Scale Population Study

2022 ◽  
Author(s):  
You Zeng ◽  
Haohui Yu ◽  
Queran Lin ◽  
Pengpeng Ye ◽  
Junrun Zhang ◽  
...  
2020 ◽  
Vol 5 (8) ◽  
pp. 1251-1260
Author(s):  
Mannix Imani Masimango ◽  
Ernest Kiswaya Sumaili ◽  
Pierre Wallemacq ◽  
Espoir Bwenge Malembaka ◽  
Michel P. Hermans ◽  
...  

2021 ◽  
Vol Volume 14 ◽  
pp. 1107-1119
Author(s):  
Wen Ma ◽  
Wentao Wu ◽  
Rong Fu ◽  
Shuai Zheng ◽  
Ruhai Bai ◽  
...  

PLoS Genetics ◽  
2005 ◽  
Vol preprint (2007) ◽  
pp. e9
Author(s):  
Colette M Johnston ◽  
Frances L Lovell ◽  
Daniel A Leongamornlert ◽  
Barbara E. Stranger ◽  
Emmanouil T. Dermitzakis ◽  
...  

2021 ◽  
Author(s):  
Jenny Theorell‐Haglöw ◽  
Ulf Hammar ◽  
Lars Lind ◽  
Sölve Elmståhl ◽  
Eva Lindberg ◽  
...  

Author(s):  
Jin-Yu Zhang ◽  
Ding-Wen Wu ◽  
Ru-Lai Yang ◽  
Lin Zhu ◽  
Meng-Yi Jiang ◽  
...  

2019 ◽  
Vol 03 (01) ◽  
pp. 071-080
Author(s):  
Ghassan El-Haddad

AbstractPeptide receptor radionuclide therapy (PRRT), a targeted form of systemic radiotherapy allowing the delivery of radionuclides directly to tumor cells, has been used for more than three decades in the treatment of advanced neuroendocrine tumors (NETs) exhibiting high levels of somatostatin receptors. Recently, 177Lu-DOTATATE, a radiolabeled somatostatin analog, was approved by the US Food and Drug administration for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. Early phase I and II studies have shown the benefits of PRRT, but it was the NETTER-1 trial (a large-scale randomized multicenter trial for progressive well-differentiated advanced or metastatic somatostatin receptor-positive midgut carcinoid tumors) that provided high-level evidence of improved overall response rate, and progression-free survival compared with long-acting octreotide. In this article, we will discuss the evolution, clinical applications, and implementation of PRRT, as well as potential future strategies to enhance its clinical efficacy in the treatment of GEP-NETs.


Sign in / Sign up

Export Citation Format

Share Document